| Date Filed | Type | Description |
| 02/16/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/10/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 12/22/2020 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)]: |
| 12/08/2020 |
4
| Endo International plc (10% Owner) has filed a Form 4 on BIOSPECIFICS TECHNOLOGIES CORP|
Txns:
| Bought 7,344,955 shares
@ $88.5, valued at
$650M
|
|
| 12/02/2020 |
4
| Chao Jennifer M (Director) has filed a Form 4 on BIOSPECIFICS TECHNOLOGIES CORP|
Txns:
| Disposed/sold 1,920 shares
@ $0
Disposed/sold 1,726 shares
@ $0
Disposed/sold 1,687 options to buy
@ $37.64, valued at
$63.5k
Disposed/sold 15,000 options to buy
@ $41.82, valued at
$627.3k
Disposed/sold 5,000 options to buy
@ $55.62, valued at
$278.1k
|
|
| 12/02/2020 |
4
| Wegman Toby (10% Owner) has filed a Form 4 on BIOSPECIFICS TECHNOLOGIES CORP|
Txns:
| Disposed/sold 1,890 shares
@ $0
Disposed/sold 1,726 shares
@ $0
Disposed/sold 935,073 shares
@ $0 |
|
| 12/02/2020 |
4
| Fishman Corey N. (Director) has filed a Form 4 on BIOSPECIFICS TECHNOLOGIES CORP|
Txns:
| Disposed/sold 2,018 shares
@ $0
Disposed/sold 6,000 options to buy
@ $55.63, valued at
$333.8k
|
|
| 12/02/2020 |
4
| Wegman Mark N (10% Owner) has filed a Form 4 on BIOSPECIFICS TECHNOLOGIES CORP|
Txns:
| Gifted 2,400 shares
@ $0
Disposed/sold 64,762 shares
@ $0
Disposed/sold 1,726 shares
@ $0
Disposed/sold 935,073 shares
@ $0 |
|
| 12/02/2020 |
4
| Schamroth Michael (Director) has filed a Form 4 on BIOSPECIFICS TECHNOLOGIES CORP|
Txns:
| Disposed/sold 115,890 shares
@ $0
Disposed/sold 1,726 shares
@ $0 |
|
| 12/02/2020 |
4
| Truitt Joseph (CEO) has filed a Form 4 on BIOSPECIFICS TECHNOLOGIES CORP|
Txns:
| Disposed/sold 100,000 options to buy
@ $63.72, valued at
$6.4M
|
|
| 12/02/2020 |
4
| Gitman Paul (Director) has filed a Form 4 on BIOSPECIFICS TECHNOLOGIES CORP|
Txns:
| Disposed/sold 16,890 shares
@ $0
Disposed/sold 1,726 shares
@ $0 |
|
| 12/02/2020 |
4
| HUTCHISON PATRICK (CFO) has filed a Form 4 on BIOSPECIFICS TECHNOLOGIES CORP|
Txns:
| Disposed/sold 10,000 options to buy
@ $56.21, valued at
$562.1k
|
|
| 12/02/2020 |
4
| Sherman Michael A. (Director) has filed a Form 4 on BIOSPECIFICS TECHNOLOGIES CORP|
Txns:
| Disposed/sold 2,018 shares
@ $0
Disposed/sold 6,000 options to buy
@ $55.63, valued at
$333.8k
|
|
| 12/02/2020 |
SC 13D/A
| Wegman Toby reports a 0% stake in § 240. BioSpecifics Technologies Corp. |
| 12/02/2020 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 12/02/2020 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 12/02/2020 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 12/02/2020 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 12/02/2020 |
RW
| Form RW - Registration Withdrawal Request: |
| 12/02/2020 |
8-K
| Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta...|
Docs:
|
"Amended and Restated Certificate of Incorporation of BioSpecifics Technologies Corp",
"Amended and Restated By-laws of BioSpecifics Technologies Corp",
"BioSpecifics Announces Completion of Acquisition by Endo Pharmaceuticals WILMINGTON, DE - December 2, 2020 - BioSpecifics Technologies Corp. , a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX ® in North America, today announced the successful completion of its acquisition by Endo International plc for approximately $658.2 million in equity value. Endo's all-cash tender offer to acquire all of the issued and outstanding shares of BioSpecifics' common stock at a purchase price of $88.50 per share expired one minute after 11:59 p.m., New York time, on December 1, 2020. Computershare Trust Company, N.A., the depositary and paying agent for the Offer, reported that approximately 6..." |
|
| 12/02/2020 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 12/02/2020 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 12/02/2020 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 11/18/2020 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 11/18/2020 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 11/09/2020 |
10-Q
| Quarterly Report for the period ended September 30, 2020 |
| 11/09/2020 |
8-K
| Quarterly results |
| 11/06/2020 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 11/06/2020 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 11/02/2020 |
SC 14D9
| Form SC 14D9 - Solicitation, recommendation statements: |
| 11/02/2020 |
SC TO-T
| Form SC TO-T - Tender offer statement by Third Party: |
| 10/29/2020 |
3
| Endo International plc (See footnotes (1)(2)(3)(4)) has filed a Form 3 on BIOSPECIFICS TECHNOLOGIES CORP |
| 10/29/2020 |
SC 13D
| Endo International plc reports a 12.7% stake in BIOSPECIFICS TECHNOLOGIES CORP. |
| 10/19/2020 |
SC TO-C
| Form SC TO-C - Written communication relating to an issuer or third party: |
|